首页 | 本学科首页   官方微博 | 高级检索  
检索        


Human menstrual blood-derived stem cells as immunoregulatory therapy in COVID-19: A case report and review of the literature
Authors:Juan Lu  Zhong-Yang Xie  Dan-Hua Zhu  Lan-Juan Li
Institution:Juan Lu, Zhong-Yang Xie, Dan-Hua Zhu, Lan-Juan Li, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang Province, China
Abstract:BACKGROUNDThe coronavirus disease 2019 (COVID-19) caused by novel coronavirus 2019 in December 2019 has spread all around the globe and has caused a pandemic. There is still no current effective guidance on the clinical management of COVID-19. Mesenchymal stem cell therapy has been shown to be one of the therapeutic approaches to alleviate pneumonia and symptoms through their immunomo-dulatory effect in COVID-19 patients.CASE SUMMARYWe describe the first confirmed case of COVID-19 in Hangzhou to explore the role of human menstrual blood-derived stem cells (MenSCs) in the treatment of COVID-19. Moreover, we review the immunomodulation effect including non-specific and specific immune functions of MenSCs for the therapy of COVID-19.CONCLUSIONMenSCs can be helpful to find a promising therapeutic approach for COVID-19.
Keywords:COVID-19  Human menstrual blood-derived stem cells  Immunoregulatory therapy  Inflammatory response  Cytokine storm  Case report
本文献已被 维普 等数据库收录!
点击此处可从《》浏览原始摘要信息
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号